- Can Autodesk and Organovo Bring Tissue Engineering to a Hospital Near You?
New light is shed on a forgotten collaboration between Autodesk and Organovo to inject predictability into the design of living systems.
- Is Wall Street Still a Liability for Solazyme Investors?
Optimism surrounds Solazyme, and rightfully so, but Wall Street analysts should not be your sole source of information.
- The World's Leading Tire Manufacturers Are Turning to Synthetic Biology -- But Not for the Reason Yo
Forget sustainability -- 13 of the world's leading tire manufacturers are eyeing Amyris' synthetic biology platform for a completely different reason.
- How Genetic Engineering Can Save the Iconic American Chestnut Tree
More precise than cross-breeding methods, genetic engineering provides the best shot at restoring the environmental and economic importance of the American chestnut.
- Can Amyris Inc. Save Deep-Sea Sharks and Expand This Market by 230%?
Many personal care products you use on a daily basis manufactured by Avon, Unilever, and Procter & Gamble use a rare ingredient called squalane. Unfortunately, about 40% of the global supply comes from deep-sea shark catches. Luckily, Amyris has a solution.
- How Craig Venter Plans to Challenge Google in the Race to Enhance Human Health
Everyone thought Google was crazy for trying to find solutions to major problems facing human health. So what will they say when they discover Google isn't alone in its ambitious quest?
- Bill Gates' Dream for a Nuclear-Powered Future Is Almost Here
Like it or not, nuclear energy remains the safest and cleanest energy source. Could reactors that consume nuclear waste developed by General Electric, TerraPower, and Babcock & Wilcox make Bill Gates' dream a reality?
- How Designer Microbes and the Organism Industry Will Reshape Our World
Many investors are captivated by the future of companies such as Tesla Motors and 3-D Systems -- and the potential creation of shareholder value on a scale that will be difficult to match. But are investors overlooking an even more promising industry with a brighter future?
- Attention, Solazyme Investors: Don't Forget About Amyris
Synthetic biology pioneer Amyris discussed its full-year 2013 results after market close. Here's what investors need to know about 2013 and what you can expect from operations in 2014.
- Can Solazyme Inc Successfully Scale Biology?
Renewable oils company Solazyme recently announced the start-up of commercial operations at its Clinton, Iowa facility. The market sent shares 30% higher, but past obstacles in scaling biology at Amyris and Gevo may hint that the spike was a bit premature.